Mr. Rubino commented, "I was attracted to Emisphere by the broad potential of its Eligen® Technology to improve therapeutic delivery of vital pharmaceutical products and the Company's goal to pursue an IMMEDIATE COMMERCIAL OPPORTUNITY to create value by launching its market-ready Eligen® Oral B12 product."
I don't always drink beer, but when I do, I prefer Dos Equis..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.